Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 20, 2007

GenVec Signs CRADA with the NIAID to Develop RSV Vaccines

  • GenVec signed a CRADA with the NIAID to develop adenovector-based vaccines for the prevention and treatment of respiratory syncytial virus (RSV).

    The collaborative research will combine NIAID's scientific and clinical expertise in RSV with GenVec's experience in development of adenovector-based vaccines and manufacturing process.

    In addition to the RSV collaboration, GenVec is working with the NIAID on the clinical development of HIV and influenza vaccines. "Data emerging from the clinical trials of our HIV vaccine candidate indicates that GenVec's adenovector technology induces both antibodies and cellular immune responses," notes Rick King, GenVec's senior vp of research. "This has the potential to be highly effective in preventing RSV-induced disease."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »